・Adaptive Biotechnologies (ADPT) is a commercial-stage biotech with strong technical momentum. ・Shares are up 250% in the past year and just hit a new three-year high. ・ADPT maintains a 100% “Buy” ...
Wall Street firm Jefferies believes certain biotechnology stocks are poised to benefit from AI advancements. Analyst Michael Yee told CNBC that the sector is likely to save billions of dollars as well ...
Akari Therapeutics is an oncology biotechnology company developing next-generation spliceosome payload antibody drug conjugates (ADCs). Utilizing its innovative ADC discovery platform, the Company has ...
The biotechnology market is entering a new growth phase, driven by the convergence of genomic science, artificial intelligence, and precision medicine, as global R&D investment approaches $360 billion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results